Zepbound cost: what you pay in 2026, and what moves the price

Zepbound® is Eli Lilly's brand of tirzepatide, approved for chronic weight management. What it costs you depends almost entirely on one thing: whether your insurance plan covers it. With coverage and a manufacturer savings card, the monthly cost can fall to a copay. Without coverage, you are looking at the manufacturer's self-pay channel, a cash price at a pharmacy, or the list price, and those three numbers are very far apart.

This page sets out the real price points, what moves them and where each current figure is published, then covers how the medication works, how to dose and inject it, and how it differs from Mounjaro®, which contains the same active ingredient. Society does not dispense Zepbound. What Society does offer instead, and how it differs, is set out plainly further down this page.

There is no single Zepbound price. There are four different numbers, and which one applies to you depends on your plan and where you fill the prescription. Figures below are approximate and current as of September 2026, and each row names the channel that publishes the live number.

Self-pay pricing has been reset more than once since 2024, which is why the table points you at the manufacturer's own channel for that figure rather than printing a number that ages badly. The list price is the stable one, and the right one to anchor on when you are judging whether an offer you have been shown is real.

Three things set the price, and none of them is the cost of making it.

It is on patent. Tirzepatide has no generic in the United States, so there is no second manufacturer to price against. That competition is the usual mechanism that brings a drug's price down, and it does not exist here yet.

List price and net price are different numbers. Manufacturers negotiate rebates with pharmacy benefit managers in exchange for formulary position. Those rebates never appear at the counter, which is why the price a plan pays and the price you pay can move in opposite directions.

Weight management sits outside a lot of benefit designs. Many plans exclude the category outright rather than placing it on a high tier, so the whole cost lands on one person instead of a risk pool. That exclusion, more than the sticker price, is what makes Zepbound expensive for most people searching for what it costs.

Medicare and Medicaid are their own question. Federal rules have historically restricted coverage of medications prescribed purely for weight loss, and coverage tied to a different approved use of the same drug can be treated differently. Check your plan's current formulary, including any coverage attached to the obstructive sleep apnea indication.

If your plan excludes weight management medication, or you have no plan at all, you still have routes. None of them is free, and you should price all of them before committing to one.

Manufacturer self-pay vials. Eli Lilly sells Zepbound in single-dose vials through LillyDirect, its self-pay channel, at prices well below the list price of the pens. You still need a prescription. The vials are drawn up with a separate syringe rather than delivered by an autoinjector, so administration differs from the pen.

Cash price at a pharmacy. Cash prices vary by pharmacy and by discount card. Call two or three, because the spread is real and it is larger than most people expect.

The same molecule under a different brand. Tirzepatide is also sold as Mounjaro, which is approved for type 2 diabetes rather than weight management. A prescriber can only prescribe where it is clinically appropriate, so this is not a workaround for a coverage problem. It matters mainly if you have type 2 diabetes, in which case the coverage picture for Mounjaro may look nothing like the one for Zepbound.

A different molecule. Semaglutide is a different drug in a related class, sold as Wegovy for chronic weight management. Plans that exclude one sometimes cover the other, so check both before assuming you are stuck.

What Society does offer is clinician-prescribed compounded tirzepatide from $249 per month, injected once a week. Society also dispenses brand Mounjaro® from $1,395 per month, the same molecule as Zepbound but approved for type 2 diabetes rather than weight management, and brand Wegovy® from $1,695 per month, which is semaglutide and does carry the chronic weight management approval.

Compounded tirzepatide is not Zepbound, and the difference matters. Zepbound is an FDA approved product with an approved label, an approved indication and a manufacturing standard FDA inspects. Compounded tirzepatide is prepared by a pharmacy for an individual patient on a clinician's direction. Compounded medications are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy, or quality. A compounded formulation is not a generic Zepbound, is not equivalent to it and is not interchangeable with it, and whether one is appropriate is a clinical decision a licensed US practitioner makes for a specific patient, not an option you select from a menu. Our compounded versus brand GLP-1 page sets out how the rules have narrowed since 2025.

What a Society plan includes. A free 2-minute evaluation to start, then a personalized treatment plan, the medication, labs, expedited shipping and continuous clinical assistance. Most members hear back from a provider within a day or two, delivery is free, discreet and takes 1 to 2 days, prescribing is by licensed US practitioners through US licensed pharmacies, and no insurance is required. More than 10,000 patients have been treated, and support typically replies within 24 hours. You can pause, switch or cancel anytime, and the first two months of any treatment plan are strictly non-refundable. Providers are licensed in the state where the patient is located at the time of consultation, so availability may vary by state.

Zepbound contains tirzepatide, which acts on two gut hormone receptors rather than one. It is an agonist at both the GIP receptor (glucose-dependent insulinotropic polypeptide) and the GLP-1 receptor (glucagon-like peptide-1). Most other medications in this category act on GLP-1 alone.

Appetite signaling. Both pathways act on regions of the brain involved in appetite and food intake, which for most people shows up as feeling full sooner and thinking about food less.

Gastric emptying. Food leaves the stomach more slowly, which extends fullness after a meal and is also the source of most gastrointestinal side effects.

Glucose handling. Insulin release increases in a glucose-dependent way and glucagon falls, which is why the same molecule is used in type 2 diabetes under a different brand name.

Tirzepatide is given once a week by subcutaneous injection, on the same day each week, at any time of day, with or without food.

Same active ingredient, different approved use. Zepbound and Mounjaro are both tirzepatide, both made by Eli Lilly, and both available in the same six strengths from 2.5 mg to 15 mg once weekly. What separates them is the indication FDA approved each one for. Mounjaro is approved to improve blood sugar control in adults with type 2 diabetes. Zepbound is approved for chronic weight management and for obstructive sleep apnea in adults with obesity.

So the honest answer to both "is Zepbound the same as Mounjaro" and "is Mounjaro the same as Zepbound" is this: the drug is the same, the product is not. They are separate prescription products with separate labels, separate packaging and separate insurance treatment. A pharmacy cannot substitute one for the other, your prescriber has to write for the specific product, and plans frequently cover one while excluding the other.

More on both in our Mounjaro page, and on the underlying molecule across both brands in our tirzepatide page.

Zepbound comes in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, each given once weekly. The starting dose is for tolerance, not for effect.

What is the highest dose of Zepbound?
‍
15 mg once weekly is the maximum. There is no approved dose above it, and taking more than one dose in a week is not a way to get there faster. If you miss a dose, take it within four days (96 hours) of the scheduled day. If more than four days have passed, skip it and take the next dose on your normal day.

What dose of Zepbound is most effective?
‍
In the 72-week SURMOUNT-1 trial, the 15 mg dose produced the largest average reduction in body weight and 10 mg was close behind, with 5 mg lower again (Eli Lilly, Zepbound prescribing information). So on trial averages, higher doses produced larger average results.

That is not the same as the highest dose being the right dose for you. The dose that works is the lowest one that produces a clinically meaningful result you can tolerate and stay on. Some people reach that at 5 mg and never need to go higher. Others escalate to 15 mg. Side effects are dose-related, and a dose you stop taking because of nausea is not an effective dose. This is a decision to make with your prescriber, using how you are actually responding, not a number to aim for.

Zepbound is injected subcutaneously, which means into the fat layer just under the skin rather than into muscle. Rotate the site each week, do not use the exact same spot twice in a row, avoid skin that is tender, bruised, red, hard or scarred, and do not inject through clothing.

How to inject Zepbound with the single-dose pen

With the single-dose vials the technique is different: you draw the dose up into a syringe supplied for that purpose. Our general injection guide covers technique in more detail. Always follow the Instructions for Use supplied with your product, because device designs and their instructions change, and the leaflet in your box is the one that applies to you.

Does Zepbound need to be refrigerated?
‍
Yes, as the default. Store Zepbound in a refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect it from light. If you need to, it can be stored at room temperature up to 86°F (30°C) for up to 21 days, and once it has been at room temperature it should not go back in the fridge for long-term storage.

Never freeze it. Do not use Zepbound that has been frozen, even if it has thawed and looks normal, and do not use it if it is cloudy, discolored or has particles in it. When traveling, keep it in the original carton, carry it in hand baggage rather than checked baggage, and use an insulated bag with a cool pack that does not touch the pen directly.

Zepbound is FDA approved, which means FDA judged its benefits to outweigh its risks for the populations on its label. That is not the same as safe for everyone, and the label carries a boxed warning.

Boxed warning: risk of thyroid C-cell tumors. In rodent studies, tirzepatide caused thyroid C-cell tumors. It is not known whether it causes these tumors, including medullary thyroid carcinoma, in humans. Zepbound must not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC), or by anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of its ingredients, or if either of the boxed warning conditions applies to you. Tell your prescriber if you are pregnant, planning to become pregnant, or breastfeeding.

Serious risks in the prescribing information include pancreatitis, gallbladder problems including gallstones, low blood sugar (particularly with insulin or a sulfonylurea), serious allergic reactions, acute kidney injury from dehydration, vision changes in people with type 2 diabetes, depression or thoughts of suicide, severe stomach problems, and food remaining in the stomach during general anesthesia or deep sedation, which you must disclose to any surgeon or anesthesiologist before a procedure.

The most common side effects are nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, allergic reactions, burping, hair loss and heartburn (Eli Lilly, Zepbound prescribing information). This is a summary, not the full label. Read the complete prescribing information and medication guide, and our Zepbound safety information.

How long do Zepbound side effects last?
‍
For most people, gastrointestinal side effects are worst in the days right after a dose increase and settle over the following one to three weeks as the body adjusts. That is why the schedule holds each dose for four weeks: the step exists to let tolerance develop before the next increase.

Side effects that do not settle, or that worsen, are a reason to contact your prescriber rather than push through. Slowing the escalation, staying longer at the current dose, or stepping back down are all normal adjustments. Severe or persistent abdominal pain, especially pain radiating to the back, needs urgent medical attention.

Does Zepbound cause hair loss?
‍
Hair loss is listed among the adverse reactions in the Zepbound prescribing information, reported more often in participants taking tirzepatide than in those on placebo. The prescribing information is where the reported rates are published, and it is worth reading that section rather than a summary of it.

Shedding after substantial, rapid weight loss is also a recognized phenomenon in its own right, telogen effluvium, and it is usually temporary. It is typically driven by the physiological stress of rapid weight reduction and by reduced protein and micronutrient intake when appetite falls, rather than by the drug acting on hair follicles. Adequate protein, not cutting calories below your plan, and checking iron, ferritin, vitamin D and thyroid function are all reasonable steps. Raise it with your clinician rather than stopping treatment on your own.

What can be said is what the trials showed, as group averages. In SURMOUNT-1, a 72-week trial in adults with obesity or overweight without type 2 diabetes, participants taking tirzepatide alongside a reduced-calorie diet and increased physical activity lost an average of roughly 15% to 21% of body weight depending on dose, compared with roughly 3% on placebo (Eli Lilly, Zepbound prescribing information).

Three months is a different question from 72 weeks, and the dosing schedule is why. The first 12 weeks are four weeks at 2.5 mg, a tolerance-building dose, then 5 mg and possibly 7.5 mg. Most of the trial's total reduction accrued after that, at maintenance doses held over many months. So the first three months are where the dose gets established and the habits get built, not where the headline numbers appear. Judging the medication on a 12-week result is judging it before it has finished starting.

Regain after stopping is documented too. In SURMOUNT-4, participants switched to placebo after an initial treatment period regained a substantial share of the weight lost, while those who continued largely maintained it. Treat this as a long-term medication, not a 12-week course.

Society does not dispense Zepbound. This is how treatment with Society itself works, whichever medication a licensed US practitioner decides is appropriate for you, and it begins with a free 2-minute evaluation rather than a purchase.

Society does not dispense Zepbound. It does offer compounded tirzepatide from $249 per month, compounded semaglutide from $149 per month, brand Wegovy from $1,695 per month and brand Mounjaro from $1,395 per month. A free 2-minute evaluation tells you which, if any, a licensed US practitioner thinks is right for you.

* Individual results may vary, and not all patients will qualify for treatment. Always consult a licensed healthcare provider before starting or modifying any medical treatment.

Society facilitates access to consultations with independent, licensed healthcare providers who evaluate each patient and determine eligibility for treatment. Prescription products require an online medical evaluation. Medications are prescribed by independent physicians and dispensed by licensed U.S. pharmacies or a patient's preferred pharmacy. Only a qualified healthcare provider can determine whether a treatment is appropriate for an individual's specific medical needs.
Providers are licensed in the state where the patient is located at the time of consultation, and availability may vary by state.
Society's services are intended for individuals 18 years of age or older. Age verification may be required as part of the intake process.
‍Society partners with licensed U.S. pharmacies. Certain treatments may include compounded medications, which are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy, or quality. Compounded medications may be prescribed by a healthcare provider based on individual patient needs or during periods of drug shortages. FDA-approved GLP-1 medications—such as Ozempic® (semaglutide), Wegovy® (semaglutide), and Zepbound® (tirzepatide)—are not compounded. Society is not affiliated with, endorsed by, or sponsored by the manufacturers of these products. All trademarks and brand names belong to their respective owners.
GLP-1–based treatments may carry risks, including the potential for thyroid C-cell tumors. These medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Please consult a healthcare provider for complete prescribing and safety information.
Prescription medications are dispensed only when determined appropriate by a licensed healthcare provider following an online medical evaluation. No prescription is guaranteed, and treatment decisions are made solely at the prescriber's clinical discretion.
Statements on this website have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Images shown are for illustrative purposes only; actual product appearance may vary.